Skip to main content

Acute Coronary Syndrome

Cardiovascular
54
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
10
0
16
20
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
563%
Monoclonal Antibody
113%
Peptide
113%
RNA Therapeutic
113%
+ 115 programs with unclassified modality

Acute Coronary Syndrome is a $725M market dominated by a single peak-stage product with limited competitive diversity.

$0.725B marketMature→ Stable4 products10 companies

Key Trends

  • BRILINTA (ticagrelor) commands 95% of market spending, creating concentration risk
  • P2Y12 receptor antagonists represent 96% of spending; older mechanisms like GP IIb/IIIa inhibitors are declining
  • Significant patent cliff approaching 2035-2036 when BRILINTA loses exclusivity

Career Verdict

Moderate career bet: strong job availability and revenue base, but limited growth runway and high dependence on a single aging product make this a stabilizing rather than expanding opportunity.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1BRILINTAStable
$0.692B
AstraZeneca·Peak10.2yr
#2PLAVIXDeclining
$0.007B
Sanofi·LOE Approaching
#3KENGREALStable
Chiesi·Peak9.2yr
#4INTEGRILINDeclining
Merck & Co.·LOE Approaching

Drug Class Breakdown

P2Y12 Receptor Antagonists
$0.699B(96%)

Dominates market; BRILINTA sole growth driver

GP IIb/IIIa Inhibitors (eptifibatide)
(0%)

Declining; niche acute care setting

Career Outlook

Stable

ACS is a mature, consolidated market with stable employment but limited upside. AstraZeneca's BRILINTA dominance creates job security through 2035-2036, but the approaching patent cliff and sparse pipeline mean professionals should expect layoffs and re-organization post-2035. This is a defensible career choice for early-to-mid career commercial talent seeking stability, but not for those seeking innovation exposure or rapid advancement.

Breaking In

Enter via AstraZeneca or Sanofi sales/marketing roles to build cardiology expertise and commercial fundamentals; avoid R&D roles given sparse pipeline.

For Experienced Professionals

Experienced professionals should seek Medical Affairs, clinical operations, or market access roles where salary premiums ($300K+) offset limited growth; plan exit strategy before 2034 patent cliff.

In-Demand Skills

Cardiovascular pharmacology and thrombosis mechanismsRegulatory and post-approval safety management (Phase 4)Commercial excellence in mature market maintenanceReal-world evidence generation and health economics

Best For

Brand Manager (Mature Asset)Medical Science Liaison (Cardiologist-facing)Clinical Safety OfficerCommercial Analytics / Market Access Manager

Hiring Landscape

$112K-$307K

AstraZeneca dominates hiring with 1,373 jobs tied to ACS portfolio, followed by Sanofi (1,121 jobs) and Takeda (1,335 jobs). Commercial roles represent 1,589 positions (67% of total identified ACS hiring), reflecting the mature, promotion-driven nature of the market. Clinical Operations and Medical Affairs roles command premium salaries ($307K and $302K respectively), signaling competition for regulatory and safety expertise.

7,779
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

AstraZeneca
1373Stable
Takeda
1335Stable
Sanofi
1121Stable

By Department

Commercial(20%)
$257K
Clinical Operations(5%)
$307K
Medical Affairs(3%)
$302K

Hiring is concentrated at mature-stage companies managing established assets; growth opportunities are limited, and competition for high-paying clinical/medical roles is fierce.

On Market (1)

Approved therapies currently available

AstraZeneca
BRILINTAApproved
ticagrelor
AstraZeneca
P2Y12 Platelet Inhibitor [EPC]oral2011
692M Part D

Competitive Landscape

51 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
24 programs
3
3
7
TicagrelorPhase 41 trial
TicagrelorPhase 41 trial
TicagrelorPhase 41 trial
TicagrelorPhase 41 trial
Ticagrelor + ASA + BivalirudinPhase 41 trial
+19 more programs
Active Trials
NCT01490645Completed1,006Est. Aug 2014
NCT02615704Completed677Est. Mar 2019
NCT03823547Recruiting99,999Est. Jun 2050
+20 more trials
Abbott
AbbottABBOTT PARK, IL
9 programs
1
2
BS-DESPhase 41 trial
Triage CardioProfilERPhase 41 trial
ARCHITECT STAT High Sensitive Troponin I AssayPhase 31 trial
ESC 0/1 hour troponin pathwayN/A1 trial
High-sensitivity troponin I assayN/A1 trial
+4 more programs
Active Trials
NCT05322395Unknown3,536Est. Nov 2024
NCT01852123Completed48,282Est. Mar 2017
NCT01172990Terminated108Est. Feb 2014
+6 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
8 programs
2
1
2
1
fondaparinux background and standard dose UFHPhase 4
Darapladib 160 mgPhase 3
Losmapimod 7.5 mg twice dailyPhase 3
GW856553Phase 2
LosmapimodPhase 1
+3 more programs
Prevail Therapeutics
6 programs
2
2
1
Modification of Prasugrel based on a biological assayPhase 41 trial
ClopidogrelPhase 31 trial
PrasugrelPhase 31 trial
PrasugrelPhase 21 trial
PrasugrelPhase 21 trial
+1 more programs
Active Trials
NCT01088503Completed12,227Est. Jan 2014
NCT01115738Completed282Est. Nov 2011
NCT00385944Completed56Est. Oct 2007
+3 more trials
UNION therapeutics
3 programs
2
ColchicinePhase 41 trial
allopurinol sustained-release capsulesPhase 41 trial
Bleeding Risk Assessment System for Antithrombotic Therapy of ACSN/A1 trial
Active Trials
NCT04162808Unknown6,379Est. Dec 2023
NCT04848857Completed128Est. Oct 2023
NCT03745729Completed162Est. Jul 2022
Boston Scientific
3 programs
1
BS-DESPhase 4
SYNERGY stentN/A1 trial
iMAPN/A1 trial
Active Trials
NCT02890589Completed22Est. Feb 2018
NCT01437553Completed100Est. Mar 2013
Sharp Therapeutics
3 programs
1
1
EnoxaparinPhase 4
PantoprazolePhase 1Small Molecule
simvastatinN/ASmall Molecule
MSD
MSDIreland - Ballydine
3 programs
1
1
EnoxaparinPhase 41 trial
PantoprazolePhase 1Small Molecule1 trial
simvastatinN/ASmall Molecule1 trial
Active Trials
NCT00725829Unknown100Est. Dec 2009
NCT01358344Completed173Est. Dec 2010
NCT00790387Completed60Est. Dec 2006
Integrated Biosciences
2 programs
1
Point of Care testingPhase 41 trial
Data CollectionN/A
Active Trials
NCT01563250Completed705Est. Dec 2011
Biocorp
1 program
1
ClopidogrelPhase 41 trial
Active Trials
NCT01572129Unknown240
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Same-day dischargePhase 41 trial
Active Trials
NCT01068119Terminated57Est. Mar 2012
Pfizer
PfizerNEW YORK, NY
3 programs
1
1
ApixabanPhase 3
ApixabanPhase 2
DalteparinN/A1 trial
Active Trials
NCT00922766Completed618Est. Sep 2010
Sandoz
SandozAustria - Kundl
2 programs
1
InclisiranPhase 3RNA Therapeutic1 trial
A Comparison of the TIMI, GRACE and HEART ScoresN/A1 trial
Active Trials
NCT01398631Completed2,440Est. Jul 2011
NCT04873934Completed400Est. Aug 2024
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
2 programs
1
Guardian SystemPhase 32 trials
PMA P150009 AngelMed Guardian® SystemN/A1 trial
Active Trials
NCT05412927Recruiting500Est. Dec 2026
NCT04316481Terminated17Est. Jan 2022
NCT00781118Completed1,020Est. May 2017
DalCor Pharmaceuticals
2 programs
2
DalcetrapibPhase 31 trial
dalcetrapibPhase 3
Active Trials
NCT05918861Recruiting2,000Est. Aug 2027
CSL Seqirus
1 program
1
Apolipoprotein A-I [human]Phase 3
Medpace
MedpaceCINCINNATI, OH
1 program
1
dalcetrapibPhase 31 trial
Active Trials
NCT02525939Completed6,147Est. Oct 2021
deCode Genetics
1 program
1
veliflaponPhase 31 trial
Active Trials
NCT00353067Suspended3,450
Kite Pharma
1 program
1
RanolazinePhase 21 trial
Active Trials
NCT01767987Terminated6Est. Apr 2014
Astellas
AstellasChina - Shenyang
1 program
1
YM150Phase 21 trial
Active Trials
NCT00994292Completed1,276Est. Mar 2011
AdvanceCOR
1 program
1
revaceptPhase 23 trials
Active Trials
NCT03312855Completed334Est. Mar 2020
NCT01645306Completed158Est. Sep 2019
NCT01042964Completed30Est. Oct 2007
Ildong Pharmaceutical
2 programs
2
APD791Phase 11 trial
ClopidogrelPhase 11 trial
Active Trials
NCT02419820Terminated104Est. Apr 2016
NCT02034292Terminated16Est. Mar 2014
Chong Kun Dang Pharmaceutical
1 program
1
D578Phase 11 trial
Active Trials
NCT03671941Completed31Est. Jun 2018
CorVivo
1 program
1
Epicardial Infarct Repair with CorMatrix-ECMPhase 11 trial
Active Trials
NCT02887768Completed8Est. Oct 2017
Sanofi
SanofiPARIS, France
4 programs
A Comparison of the TIMI, GRACE and HEART ScoresN/A
Decision Support SystemN/A1 trial
LixisenatidePHASE_3Peptide1 trial
Percutaneous Coronary InterventionPHASE_31 trial
Active Trials
NCT05844566Completed1,139Est. Dec 2024
NCT01147250Completed6,068Est. Feb 2015
NCT01014273Completed7,021Est. Mar 2011
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
4 programs
ADP receptor inhibitorsN/A
Immediate Invasive ManagementN/A
PrasugrelPHASE_3
30-day DAPTPHASE_41 trial
Active Trials
NCT04436978Recruiting2,000Est. Dec 2027
GSK
GSKLONDON, United Kingdom
4 programs
Quality Improvement ProgrammeN/A1 trial
fondaparinuxN/A1 trial
Losmapimod for single dosePHASE_11 trial
fondaparinux background and standard dose UFHPHASE_41 trial
Active Trials
NCT00716430Unknown3,500Est. Feb 2009
NCT01406301Completed1Est. Jul 2011
NCT01648192Completed20Est. Oct 2012
+1 more trials
Biotronik
BiotronikGermany - Berlin
3 programs
Percutaneous coronary interventionN/A1 trial
TicagrelorN/A1 trial
Colchicine 0.6 mgPHASE_41 trial
Active Trials
NCT03621501Active Not Recruiting1,525Est. Oct 2026
NCT02618733Completed120Est. Dec 2016
NCT06543082Recruiting490Est. Dec 2028
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
TnThs Predicting Evolving Non-STEMIN/A1 trial
TnThs for Identification Myocardial InfarctionN/A1 trial
Active Trials
NCT00953251Completed115Est. Dec 2008
NCT00950469Completed94Est. Dec 2008
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
PantoprazolePHASE_1Small Molecule
EnoxaparinPHASE_4

+21 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BiotronikColchicine 0.6 mg
Daiichi Sankyo30-day DAPT
UNION therapeuticsColchicine
UNION therapeuticsallopurinol sustained-release capsules
AstraZenecaTicagrelor
AstraZenecaticagrelor
AbbottBS-DES
AstraZenecaTicagrelor- Delayed Administration
AstraZenecaTicagrelor
AstraZenecaTicagrelor
AstraZenecaTicagrelor
AstraZenecaTicagrelor + ASA + Bivalirudin
Prevail TherapeuticsModification of Prasugrel based on a biological assay
BiocorpClopidogrel
Integrated BiosciencesPoint of Care testing

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 92,516 patients across 50 trials

NCT06543082BiotronikColchicine 0.6 mg

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Start: Aug 2024Est. completion: Dec 2028490 patients
Phase 4Recruiting
NCT04436978Daiichi Sankyo30-day DAPT

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

Start: Jan 2023Est. completion: Dec 20272,000 patients
Phase 4Recruiting
NCT04848857UNION therapeuticsColchicine

Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)

Start: May 2021Est. completion: Oct 2023128 patients
Phase 4Completed
NCT03745729UNION therapeuticsallopurinol sustained-release capsules

Allopurinol in Acute Coronary Syndrome

Start: Mar 2019Est. completion: Jul 2022162 patients
Phase 4Completed
NCT02487732AstraZenecaTicagrelor

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Start: Jul 2015Est. completion: Jan 201760 patients
Phase 4Completed
NCT02341729AstraZenecaticagrelor

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Start: Mar 2015Est. completion: Dec 201940 patients
Phase 4Completed
NCT02193971AbbottBS-DES

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

Start: Jul 2014Est. completion: Jan 20243,429 patients
Phase 4Completed
NCT01916902AstraZenecaTicagrelor- Delayed Administration

Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study

Start: Feb 20140
Phase 4Withdrawn
NCT01870921AstraZenecaTicagrelor

Brilinta DaYu Study

Start: Jun 2013Est. completion: Sep 20152,004 patients
Phase 4Completed
NCT01826175AstraZenecaTicagrelor

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Start: May 2013Est. completion: May 20140
Phase 4Withdrawn
NCT01603082AstraZenecaTicagrelor

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Start: Jul 2012Est. completion: Jun 2014343 patients
Phase 4Completed
NCT01642238AstraZenecaTicagrelor + ASA + Bivalirudin

Antithrombotic Effects of Ticagrelor Versus Clopidogrel

Start: Jul 2012Est. completion: Apr 201315 patients
Phase 4Completed
NCT01538446Prevail TherapeuticsModification of Prasugrel based on a biological assay

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Start: Mar 2012Est. completion: May 2016880 patients
Phase 4Completed
NCT01572129BiocorpClopidogrel

Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy

Start: Nov 2011240 patients
Phase 4Unknown
NCT01563250Integrated BiosciencesPoint of Care testing

Improving the Management of Acute Coronary Syndromes in the Emergency Department

Start: Jun 2011Est. completion: Dec 2011705 patients
Phase 4Completed
NCT01068119MedtronicSame-day discharge

Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)

Start: Feb 2010Est. completion: Mar 201257 patients
Phase 4Terminated
NCT00790907GSKfondaparinux background and standard dose UFH

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

Start: Feb 2009Est. completion: May 20103,235 patients
Phase 4Completed
NCT00790387MSDEnoxaparin

Tirofiban and Enoxaparin in High Risk Coronary Intervention

Start: Jun 2004Est. completion: Dec 200660 patients
Phase 4Completed
NCT00206817AbbottTriage CardioProfilER

Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)

Start: Oct 20030
Phase 4Withdrawn
NCT05918861DalCor PharmaceuticalsDalcetrapib

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Start: Oct 2023Est. completion: Aug 20272,000 patients
Phase 3Recruiting
NCT04873934SandozInclisiran

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Start: Jun 2021Est. completion: Aug 2024400 patients
Phase 3Completed
NCT03473223CSL BehringApolipoprotein A-I [human]

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Start: Mar 2018Est. completion: Nov 202318,226 patients
Phase 3Completed
NCT02525939Medpacedalcetrapib

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Start: Apr 2016Est. completion: Oct 20216,147 patients
Phase 3Completed
NCT01992523AstraZenecaTicagrelor mashed pills

Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )

Start: Nov 2013Est. completion: Apr 201482 patients
Phase 3Completed
NCT01608100AbbottARCHITECT STAT High Sensitive Troponin I Assay

Evaluation of a New Cardiac Biomarker Assay

Start: Jun 2012Est. completion: Sep 20141,101 patients
Phase 3Completed
NCT01294462AstraZenecaTicagrelor

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Start: Feb 2011Est. completion: Jul 2012801 patients
Phase 3Completed
NCT01147250SanofiLixisenatide

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Start: Jun 2010Est. completion: Feb 20156,068 patients
Phase 3Completed
NCT00830960Prevail TherapeuticsPrasugrel

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Start: Feb 2009Est. completion: Jun 2010720 patients
Phase 3Completed
NCT00781118Angel PharmaceuticalsGuardian System

AngelMed for Early Recognition and Treatment of STEMI

Start: Dec 2008Est. completion: May 20171,020 patients
Phase 3Completed
NCT00699998Prevail TherapeuticsClopidogrel

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Start: Jun 2008Est. completion: Apr 20129,326 patients
Phase 3Completed
NCT00391872AstraZenecaTicagrelor

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Start: Oct 2006Est. completion: Mar 200918,624 patients
Phase 3Completed
NCT01014273SanofiPercutaneous Coronary Intervention

A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy

Start: Jun 2006Est. completion: Mar 20117,021 patients
Phase 3Completed
NCT00353067deCode Geneticsveliflapon

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Start: May 20063,450 patients
Phase 3Suspended
NCT04601467AstraZenecaAZD5718

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

Start: Jul 2021Est. completion: Aug 2024243 patients
Phase 2Terminated
NCT03312855AdvanceCORrevacept

Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

Start: Nov 2017Est. completion: Mar 2020334 patients
Phase 2Completed
NCT02319941AstraZenecaticagrelor

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Start: May 2015Est. completion: Mar 201765 patients
Phase 2Completed
NCT01919723AstraZenecaTicagrelor

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Start: Feb 2014Est. completion: Dec 201570 patients
Phase 2Completed
NCT01645306AdvanceCORrevacept

Revacept in Symptomatic Carotid Stenosis

Start: Mar 2013Est. completion: Sep 2019158 patients
Phase 2Completed
NCT01767987Kite PharmaRanolazine

Ranolazine Cardioprotection in PCI

Start: Nov 2012Est. completion: Apr 20146 patients
Phase 2Terminated
NCT01115738Prevail TherapeuticsPrasugrel

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

Start: May 2010Est. completion: Nov 2011282 patients
Phase 2Completed
NCT00994292AstellasYM150

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

Start: Sep 2009Est. completion: Mar 20111,276 patients
Phase 2Completed
NCT00619164EisaiE5555

A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome

Start: Nov 2007240 patients
Phase 2Completed
NCT00548587EisaiE5555

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Start: Oct 2007Est. completion: Aug 2009600 patients
Phase 2Completed
NCT00385944Prevail TherapeuticsPrasugrel

The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

Start: Mar 2007Est. completion: Oct 200756 patients
Phase 2Completed
NCT03671941Chong Kun Dang PharmaceuticalD578

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers

Start: May 2018Est. completion: Jun 201831 patients
Phase 1Completed
NCT02887768CorVivoEpicardial Infarct Repair with CorMatrix-ECM

Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study

Start: Jan 2016Est. completion: Oct 20178 patients
Phase 1Completed
NCT02419820Ildong PharmaceuticalAPD791

Dose-escalation, Repeated and Single Oral Dosing Study

Start: Mar 2015Est. completion: Apr 2016104 patients
Phase 1Terminated
NCT02034292Ildong PharmaceuticalClopidogrel

Safety Study of APD-791 With Aspirin and/or Clopidogrel

Start: Feb 2014Est. completion: Mar 201416 patients
Phase 1Terminated
NCT01648192GSKLosmapimod for single dose

Phase I Study of GW856553 (Losmapimod)

Start: Jul 2012Est. completion: Oct 201220 patients
Phase 1Completed
NCT01358344MSDPantoprazole

A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Start: Aug 2010Est. completion: Dec 2010173 patients
Phase 1Completed

Related Jobs in Cardiovascular

Senior Manufacturing Engineer

BALTBALT
Irvine, California, United States
10h ago
$120K - $130K/yr

Staff Product Development Engineer

Jupiter EndovascularJupiter Endovascular
Menlo Park, CA
11h ago
$160K - $180K/yr

Application Security Engineer

HeartFlowHeartFlow
San Francisco, California
12h ago
$145K - $180K/yr

Senior Software Engineer

HeartFlowHeartFlow
San Francisco, California, United States
13h ago
$180K - $215K/yr

Staff Software Engineer

HeartFlowHeartFlow
San Francisco, California
13h ago
$190K - $250K/yr

Director, Clinical Quality Lead

KardiganKardigan
South San Francisco, California, United States, Princeton, New Jersey, United States
17h ago
$194K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 92,516 patients
30 companies competing in this space

Related Indications

Hypertension(936)Heart Failure(877)Coronary Artery Disease(769)Atrial Fibrillation(615)Pulmonary Arterial Hypertension(207)Atherosclerosis(123)Aortic Valve Stenosis(121)Pulmonary Hypertension(111)Congestive Heart Failure(94)Heart Failure, Congestive(83)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.